Condition: Pheochromocytoma/Paraganglioma · Pancreatic Neuroendocrine Tumor · Von Hippel-Lindau Disease · Sponsor: Merck Sharp & Dohme LLC
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center ( Site 0110) | Los Angeles, California, United States | Recruiting |
| Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130) | Chicago, Illinois, United States | Recruiting |
| Northwestern Medicine Cancer Center - Warrenville ( Site 0134) | Warrenville, Illinois, United States | Recruiting |
| University of Iowa ( Site 0104) | Iowa City, Iowa, United States | Recruiting |
| Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108) | Baltimore, Maryland, United States | Recruiting |
| National Institutes of Health ( Site 0125) | Bethesda, Maryland, United States | Recruiting |
| Massachusetts General Hospital ( Site 0111) | Boston, Massachusetts, United States | Recruiting |
| University of Michigan ( Site 0126) | Ann Arbor, Michigan, United States | Recruiting |
| Washington University-Internal Medicine/Oncology ( Site 0124) | St Louis, Missouri, United States | Active Not Recruiting |
| Icahn School of Medicine at Mount Sinai ( Site 0123) | New York, New York, United States | Active Not Recruiting |
| Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127) | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville, Tennessee, United States | Recruiting |
+ 72 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04924075